SCHEMBL4003586

SCHEMBL4003586

CC(C)CC[C@@](C)(C(=O)O)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C19 P33261 2/20 0.43
HIF1A Q16665 1/20 0.43
LMNA P02545 1/20 0.42
CHRM2 P08172 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
KCNH2 Q12809 1/20 0.42
KIF11 P52732 7/20 0.41
KDM4E B2RXH2 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
MAPT P10636 2/20 0.40
KMT2A Q03164 1/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
ALDH1A1 P00352 2/20 0.39
HSD17B10 Q99714 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3953264 1.00 CYP2D6 (0.44) CYP2D6CYP1A2CYP2C19HIF1ALMNA
SCHEMBL4001665 1.00 CYP2D6 (0.44) CYP2D6CYP1A2CYP2C19HIF1ALMNA
SCHEMBL3996686 0.85 HPGD (0.39) CYP2D6HIF1ALMNAKIF11MAPT
SCHEMBL3999384 0.85 HPGD (0.39) CYP2D6HIF1ALMNAKIF11MAPT
SCHEMBL4006310 0.85 HPGD (0.39) CYP2D6HIF1ALMNAKIF11MAPT
SCHEMBL3999317 0.85 CYP2D6 (0.41) CYP2D6CYP1A2CYP2C19HIF1ALMNA
SCHEMBL13903490 0.83 KCNN4 (0.50) CYP2C19HIF1ACHRM2CHRM1CHRM3
SCHEMBL1394341 0.83 CYP1A2 (0.48) CYP2D6CYP1A2CYP2C19HIF1ALMNA
SCHEMBL21273795 0.83 CYP1A2 (0.48) CYP2D6CYP1A2CYP2C19HIF1ALMNA
SCHEMBL3997211 0.82 KIF11 (0.47) CYP2D6LMNAKIF11MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538105-B2 Anti-infective agents ABBOTT LABORATORIES (US) 2009-05-26 US disclosed
US-20080193413-A1 Anti-Infective Agents ABBOTT LABORATORIES (US) 2008-08-14 US disclosed
US-7378414-B2 Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone ABBOTT LABORATORIES (US) 2008-05-27 US disclosed
US-20050107364-A1 Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone ABBVIE INC. 2005-05-19 US disclosed
WO-2005019191-A2 1, 1-DIOXIDO-4H-1,2,4-BENZOTHIADIAZINE DERIVATE UND VERWANDTE VERBINDUNGEN ALS INHIBITOREN DER HCV POLYMERASE ZUR BEHANDLUNG VON HEPATITIS C ABBOTT LABORATORIES (US) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080193413-A1 Anti-Infective Agents POLI, RPL5, POLRMT CYP2D6 448/4885CYP1A2 902/4885CYP2C19 865/4885
US-20050107364-A1 Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone POLRMT, RNASE1, RNGTT CYP2D6 793/4885CYP1A2 238/4885CYP2C19 846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.